Ivabradine reversed nondipping heart rate in rats with l-NAME-induced hypertension.
blood pressure
heart rate
hypertension
ivabradine
nondipping
Journal
Clinical and experimental pharmacology & physiology
ISSN: 1440-1681
Titre abrégé: Clin Exp Pharmacol Physiol
Pays: Australia
ID NLM: 0425076
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
17
12
2018
revised:
15
02
2019
accepted:
18
02
2019
pubmed:
23
2
2019
medline:
2
7
2020
entrez:
22
2
2019
Statut:
ppublish
Résumé
We hypothesized that decreasing elevated night-time heart rate (HR) in hypertension by administering a bradycardic agent (ivabradine) at bedtime could bring cardiovascular benefit. Since rats are nocturnal animals, they exhibit circadian rhythms phase-shifted relative to humans. Sixty-six Wistar rats were divided into non-diseased controls and rats with l-NAME-induced hypertension to compare the haemodynamic effects of daytime-dosed and night-time-dosed ivabradine. l-NAME-induced hypertension inverted the physiological 5.6% night-to-day HR dip to an undesirable HR rise by 11.1%. Ivabradine dosed at daytime (the rat's resting phase) reverted a night-to-day HR rise to HR dip by 14.2%. These results suggest a cardiovascular benefit of ivabradine dosed at the human's resting phase (night-time) for hypertensive patients with nondipping HR.
Identifiants
pubmed: 30790319
doi: 10.1111/1440-1681.13075
doi:
Substances chimiques
Ivabradine
3H48L0LPZQ
NG-Nitroarginine Methyl Ester
V55S2QJN2X
Types de publication
Letter
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
607-610Informations de copyright
© 2019 John Wiley & Sons Australia, Ltd.